Background and Purpose: Adjunctive treatments like balloon-assisted coil embolization (BACE) and stent-assisted coil embolization play a major role in the treatment of wide-neck and large intracranial aneurysms. The TransForm TM Occlusion Balloon Catheter (TOBC) registry is intended to evaluate the safety, efficacy, and efficiency of BACE using the TOBC. Method and Study Design: The TOBC registry is a prospective multicenter registry trial. Seven sites in the USA and 1 site in Spain participated and enrolled 81 patients. Results: The performance and safety of the TOBC was evaluated based on scoring for different variables. Scores were measured using a semiquantitative rating scale (1 = excellent, 5 = poor). The mean scores for these variables were as follows: visibility under fluoroscopy, 1.8; ability to reach the intended site, 1.6; stability during first positioning, 1.5; stability during inflation, 1.6; stability during deflation, 1.6; ability to temporarily stop flow, 1.6; and ability to assist in coil embolization, 1.7. The mean inflation and deflation times were 4.9 and 5.6 s, respectively. Complete obliteration of the aneurysm (Raymond class I) was achieved in 69.4% of the BACE cases. Thrombus formation occurred in 4/81 (4.8%) of the cases. In all cases, the thrombus resolved with medications, no patient suffered an infarction, and an underlying hypercoagulable state from subarachnoid hemorrhage was considered a contributing factor. Vessel rupture occurred in 1/81 (1.2%) of the cases, but was unrelated to TOBC use. Conclusion: BACE using the TOBC is safe and effective. All variables assessed for performance showed good-to-excellent results.
Introduction
In the past decade, there has been a rapid decline in clipping and a steep incline in endovascular treatment of aneurysms [1] . Although more aneurysms are now being treated with the endovascular technique, treatment of wide-neck and bifurcation aneurysms with the endovascular technique remains a challenge [2] . The difficulties include herniation of coils in the parent vessel, inability to differentiate the neck and parent vessel interface, and protection of vessel branches at the neck.
The treatment options for wide-neck aneurysms include stent-assisted coil embolization (SACE), balloon-assisted coil embolization (BACE), or treatment with flow diverters (FDs). Both SACE and FD require the use of dual antiplatelet therapy and create a theoretical longterm risk of stroke from platelet aggregation on the implant. The required use of dual antiplatelet agents limits the use of SACE or FDs in ruptured aneurysms. On the other hand, BACE does not require the use of antiplatelet agents. In 1997, Moret et al. [3] initially reported on the use of BACE, when a balloon catheter was placed across the neck of an aneurysm while Guglielmi detachable coils were deployed. Since then, several case series and case reports have been published showing the success of BACE when used with continually evolving balloon catheters [2, [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] .
Older balloon catheters like the Endeavor (Target Therapeutics, Fremont, CA, USA) and the Grapevine or Cirrus/Solstice (Medtronic-MIS Corp., Sunnyvale, CA, USA) have been taken off the market. Commonly used compliant balloon catheters include the HyperForm TM and HyperGlide TM balloons (Covidien/ev3, Irvine, CA, USA), the Scepter balloon (Scepter C TM or Scepter XC TM ; MicroVention, Inc., Tustin, CA, USA), the Ascent TM balloon (Codman Neuro, Raynham, MA, USA), and the TransForm TM balloon (Stryker Neurovascular, Fremont, CA, USA).
The Scepter is a coaxial dual-lumen compliant balloon that allows for the possibility of coil embolization through the balloon catheter utilizing a 0.014-inch wire [16, 19] . The HyperForm and HyperGlide balloon catheters are single-lumen compliant balloons utilizing 0.010-inch wires [2, 12] . The Ascent is also a coaxial dual-lumen compliant balloon catheter which can be used with a 0.014-inch wire [22] . The use of 0.010-inch wires allowed the HyperForm and HyperGlide balloons to be a smaller system, but they can be hard to navigate due to limited navigability of the 0.010-inch wire. On the other hand, the Ascent and Scepter balloons on a 0.014-inch wire have the advantage of being dual lumen, but their relatively large outer diameters can make it difficult to navigate them into distal intracranial branches.
The TransForm Occlusion Balloon Catheter (TOBC) is indicated for use in the neurovasculature to temporarily stop or control blood flow, as well as for BACE of intracranial aneu-rysms. The primary objective of this TOBC registry was to evaluate real-world data on the safety and performance of the TOBC when used in neurointerventional procedures. To our knowledge, this is the first prospective multicenter registry for BACE of intracranial aneurysms.
Device Description
The TOBC is a single-lumen, over-the-wire, compliant, and super-compliant balloon catheter having variable-stiffness reinforced catheters. The balloon is designed to provide an inflatable segment of a known diameter and length at recommended inflation volumes. The TOBC is compatible with guidewires of 0.014-inch outer diameter and 5-Fr or larger guide catheters, and has an effective length of 150 cm (Fig. 1a) .
The outer surface of the catheter's distal segment is coated with a lubricant hydrophilic coating designed to reduce friction. To facilitate fluoroscopic visualization, each catheter has two radiopaque markers at the distal and proximal ends of the balloon which are used to position the balloon at the intended treatment site. The proximal end of the balloon catheter incorporates a strain relief and a standard Luer fitting to facilitate the attachment of accessories. The delivery wire has four different material transition zones. The TOBC incorporates hundreds of micromachined slits for contrast infusion, allowing for controlled inflation and balloon stability (Fig. 1b) . In the USA, the on-label indications for use of the TOBC are for BACE, and to temporarily stop or control blood flow in the neurovasculature, while in Europe the on-label indication for use also includes the treatment of vasospasm. 
Methods

Study Design
This study was a prospective, single-arm, nonrandomized, multicenter, observational registry. Patients undergoing a neurointerventional procedure that included the use of an occlusion balloon catheter and whose anatomy allowed for safe delivery of the TOBC were enrolled. Each study site obtained approval of their respective Institutional Review Board before enrollment. All enrolled subjects consented to participation in the registry and the publication of acquired data afterwards.
Observational assessments of balloon performance were recorded by each treating physician (site principal investigator [PI]) for each case. This occurred immediately after the procedure and was done using a semiquantitative grading scale. Variables that were assessed included the ability of the TOBC to reach the target site, the ability of the TOBC to temporarily stop or control blood flow, the ability of the TOBC to assist in coil embolization of intracranial aneurysms, visibility of the TOBC on angiography, the amount of time required for the TOBC to inflate/deflate, and the stability of the TOBC during positioning and inflation/ deflation of the balloon. A 5-point rating system was used to evaluate balloon performance, with each of the 5 ratings ("excellent," "very good," "good," "fair," and "poor") being assigned a corresponding numerical value (1, 2, 3, 4, and 5) that was used to represent the TOBC's performance utility in relation to the various parameters being assessed. For a given parameter, the lower the overall number the better.
For a given subject, participation in the registry was completed upon removal of the guide catheter after the procedure. Since this was an observational registry for assessment of intraprocedural balloon performance, there was no postprocedural radiological imaging and no postprocedural follow-up visits were required. Postprocedural neurological outcomes were assessed and reported by the PIs who participated in the study.
Data Collection
Patients' age, sex, aneurysm size and location, rupture status at presentation, clinical symptoms at presentation, degree of aneurysm occlusion, type of balloon catheters and microguidewires used, amount of contrast used, inflation and deflation times, and technical and clinical complications were captured. Angiographic results were classified as described by Raymond et al. [23, 24] . All adverse events (AEs) that occurred from the time of guide catheter insertion until removal of the guide catheter were collected.
The data were collected via an Internet-accessible, secure electronic data capture system using electronic case report forms. Remote data monitoring via the electronic data capture system was utilized for this registry.
AE Definitions and Classification
An AE for this registry was defined as any untoward medical occurrence in a subject which was not related to the device under investigation. A severe AE (SAE) was defined as an AE that led to death, resulted in a life-threatening illness/injury or permanent impairment of a body structure or a body function, or required prolongation of existing hospitalization, or any medical/surgical intervention or any event that led to fetal distress, fetal death, or a congenital abnormality or birth defect in pregnant subjects.
Any untoward and unintended response to the medical device resulting from insufficiencies or inadequacies in the instructions for use, with the deployment of the device, or as a result of a user error was classified as an adverse device effect (ADE). An ADE that resulted in any of the consequences characteristic of an SAE was defined as a serious ADE. The seriousness of any AEs was assessed by the site PIs and was reported to the sponsor's project manager, the sponsor's safety manager, and the study PI. All AEs were remotely monitored, and the site PIs were responsible for assessing and reporting whether any AE occurred in relation to the study device or the index procedure. There was no independent adjudication committee for the reported events.
Statistical Analysis
Statistical analyses were performed using SAS System software version 9.4 (2000, SAS Institute, Inc., Cary, NC, USA). Descriptive statistics were used to summarize each of the various clinical and performance parameters being assessed (i.e., visibility, stability during inflation, etc.). No comparisons were performed. Data are presented as the mean and range for continuous variables and as a frequency for categorical variables. The denominator is the intent-to-treat population.
Results
Eighty-one patients were enrolled at 8 study sites between December 2013 and January 2015; 69.14% were female, and the mean age was 55 years (see Table 1 for demographics). Aneurysm characteristics were reported for 72 treatment locations (Table 2 ). Sixteen percent of the patients had more than 1 aneurysm treated; 82% (59/72) of the aneurysms were located in the anterior circulation, and 50% were ruptured. Fifty percent (36/72) of the lesions reported were bifurcation aneurysms; the location of these aneurysms was only reported for 38.9% (14/36) of these lesions, with 8/14 being M1 middle cerebral artery bifurcation lesions, and 6/14 being bifurcation lesions in the basilar artery.
The mean vessel diameter proximal to the target treated was noted for 91/92 treatment sites. The mean diameter treated was 3.29 mm (SD ±1.19), with the minimum being 1 mm and the maximum 7.4 mm.
The mean vessel diameter distal to the target treated was noted for 58/92 treatment sites. The mean diameter treated was 2.9 mm (SD ±1.3), with the minimum being 1 mm and the maximum 8 mm. The most common contrast concentrations used were 70/30 (35.9%), 50/50 (30.4%), and 100 (28.3%).
Eighty-three TOBCs were used in the trial to administer 86 treatments at 92 treatment sites in a total of 81 subjects. The most common application for use of the TOBC was BACE (73.9%). Other common uses included placement of a TOBC as a safety precaution (9.1%), and balloon test occlusion (5.7%). Uncommon or off-label uses included the treatment of vasospasm, and dilation after FD placement ( Table 3 ). The most common balloon types/sizes Table 4 .
AEs and Complications
Two subjects discontinued the study early. In one case, it was the decision of the physician to discontinue the study, as the investigator changed the treatment plan during the procedure. In this case, the subject was treated using commercially available flow diversion and adjunctive coiling as opposed to BACE. In the second case, the reason for early discontinuation was the death of the subject; this death was procedural in nature and was not directly related to TOBC use. Including the death, there were 2 SAEs and 3 AEs reported. All events (SAEs and AEs) were reported to be procedure related (Table 5) . Total number of subjects treated: n = 81; total number of TOBCs used: n = 83; total number of TOBC applications/treatments: n = 86. In 3 subjects, 1 TOBC was used to administer treatment at each of 2 treatment locations, and in 1 subject 2 TOBCs were used to administer treatment at 2 different treatment locations (with 1 TOBC being used per location). In 1 subject, 2 TOBCs were used to administer treatment at a single treatment location, as one TOBC malfunctioned and a second (replacement) TOBC had to be used to complete the procedure. TOBC, TransForm TM Occlusion Balloon Catheter; ICA, internal carotid artery. 1 For one subject, there were 2 reasons for the treatment provided (balloon-assisted coiling and as a safety precaution); likewise, for another subject there were 2 reasons for the treatment provided (balloon-assisted coiling and test occlusion). BACE, balloon-assisted coil embolization. 1 Measured on a semiquantitative rating scale: 1 = excellent, 2 = very good, 3 = good, 4 = fair, and 5 = poor. Thrombus formation occurred in 4.9% (4/81) and led to thromboembolic events in 2.5% (2/81) of the subjects. In half of these thrombotic events (1 thrombus formation and 1 thromboembolic event), balloon use was considered a contributing factor. In all cases, an underlying hypercoagulable state from subarachnoid hemorrhage was considered to be a contributing factor. In one case, the thromboembolic event, which was related to the guide catheter, led to a stroke (SAE) after the procedure.
Among the 83 device uses, there was one device malfunction reported (1.2%), and a possible TOBC inflation/deflation malfunction that was identified after the database had been locked. There were no AEs reported to be associated with device malfunction. The results for the 73.9% (65/88) of the treatments in which the TOBC was used for BACE are summarized in Table 6 .
Discussion
The management of both unruptured and ruptured cerebral aneurysms has changed drastically in the post-International Subarachnoid Aneurysm Trial (ISAT) era [4] . The ISAT showed improved outcomes with endovascular treatment of cerebral aneurysms as compared to craniotomy and clipping, particularly for aneurysms of the posterior circulation.
Advantages of BACE include the ability to treat wide-neck, complex, and bifurcation aneurysms with an endovascular technique. Another potential benefit includes the surgical equivalent of "proximal control" in cases of intraoperative rupture. The potential harmful effects of BACE include an increased risk of thromboembolic events, vessel rupture or dissection, and aneurysmal rupture or intraoperative perforation (IOP). Although there are some controversies in the literature, most of the case series do not support an increased risk of periprocedural complications with BACE as compared to traditional coil embolization [7, 12, 25] .
To our knowledge, no publication of a prospective multicenter registry for BACE exists in the literature. Real-world data for the TOBC were collected from a cohort of 81 subjects treated at a total of 8 study sites over the course of 13 months. The most common application for use of the TOBC was BACE (73.9%). Other common uses included placement of a TOBC as a safety precaution (9.1%), and balloon test occlusion (5.7%).
The TOBC performed on the higher end of the spectrum for all attributes assessed. It was easy to navigate, was stable during inflation and deflation, was highly visible, did not lose visibility with multiple inflations/deflations, and had short inflation/deflation times (see Fig. 2, 3) The guidewire technology along the length of the balloon provides faster deflation, allowing for higher contrast levels, increased visibility, and reduced procedure times. We found no previous studies that measured in vivo inflation and deflation times of a balloon. We feel the advanced design of the TOBC resulted in these short inflation and deflation times. Since average inflation time has been shown to be a predictor of thromboembolic events [14] , this may be a key performance attribute of the TOBC, but a head-to-head comparison with other balloons is needed to confirm our observation. We encourage other investigators to report this variable in studies in the future.
In this registry, thrombus formation occurred in 4.9% (4/81) and led to thromboembolic events in 2.5% (2/81) of the subjects. In half of these thrombotic events (1 thrombus formation and 1 thromboembolic event), balloon use was considered a contributing factor. In all cases, an underlying hypercoagulable state from subarachnoid hemorrhage was considered to be a contributing factor.
Thromboembolic events are considered to be the most common expected complication of BACE, although the literature is controversial. Spiotta et al. [14] have previously reported that total inflation time correlated with thromboembolic complications, not the number of balloon inflations or deflations. In the largest series of 864 BACE cases, Cekirge et al. [12] reported a rate of thromboembolic events of 1.7%. Shapiro et al. [11] reported a rate of thromboembolic events of 8.1% with BACE versus 8% with traditional coil embolization. Youn et al. [2] similarly reported an 8.8% thromboembolism risk with BACE. Sluzewski et al. [25] reported a 9.8% thromboembolic risk and an overall procedural morbidity of 14.1% when performing BACE. In this study, none of the subjects treated suffered from a thromboembolic infarction, but no information on MRI findings were collected, and therefore the rate of asymptomatic diffusion-weighted imaging lesions in our cohort was unknown. Spiotta el al. [14] reported silent diffusion-weighted imaging lesions at 21.5% in BACE cases, and 18% in traditional coil embolization cases.
Another serious complication potentially associated with BACE is IOP of an aneurysm or vessel rupture. In this study, 1 out of 81 subjects (1.2%) developed a vessel perforation during the procedure. In this case occurring in Europe, the subject was a 59-year-old male with a history of vasculitis, moyamoya disease, stroke/transient ischemic attack, and diabetes mellitus. A 5 × 15 mm compliant TOBC was used for angioplasty of the proximal basilar artery and was inflated 5 times. The rupture occurred during the last inflation. The site PI assessed the event (vessel rupture) and determined that it was unrelated to TOBC use and was related instead to the index procedure and patient comorbidities (vessel condition due to vasculitis). There was no overinflation of the balloon, and there was no device malfunction reported for this case. This subject subsequently died and represents the only mortality in this study. Previously reported IOP rates are 5.4, 2.5, 1.6, and 0.9% [11, 12, 14, 26] .
Overall, the procedural complication rates in this study were comparable to those for coil embolization. However, since a head-to-head randomization against coil embolization was not performed, direct comparisons with coil embolization cannot be made.
Our study includes all the potential biases of a prospective registry. A screen failure log was not required, and therefore selection bias could not be ruled out. Comparisons with other balloon catheters or traditional coil embolization could not be made, as this was a single-arm registry. This registry does show that the TOBC is safe to be used in neurovascular cases for BACE or balloon occlusion. It also supports results from the literature indicating that BACE does not increase the perioperative complication risk for endovascular treatment of aneurysms and can achieve favorable results for the treatment of wide-neck and bifurcation aneurysms. Caution is advised when using the TOBC for angioplasty, as safety data are limited for such an indication.
Study Limitations
This was an observational registry to evaluate real-world data on the safety and performance of the TOBC when used during neurointerventional procedures. Since the participation of each subject enrolled in the registry was completed upon removal of the guide catheter after the procedure, there were no postprocedural radiological imaging or follow-up visits required. No core laboratory was used for the assessment of the angiographic outcomes; rather, the angiographic results were classified by Raymond class and were reported by the site PIs. Observational assessments of balloon performance were made using the semiquantitative grading scale provided. This was done by the site PIs immediately after the procedure and may have varied depending on each operator's observation. There was no independent review of the images by a core laboratory or independent adjudication of the AEs by the clinical events committee.
Conclusion
In this multicenter registry, we found use of the TOBC to be safe and effective for BACE and temporary occlusion. The TOBC performed as intended in the treatment of cerebral aneurysms in our cohort of patients. All variables assessed for TOBC performance showed very good to excellent results. No serious side effects occurred. The short inflation and deflation times and the ability to use a 0.014-inch guidewire allowed for optimal performance of this balloon catheter.
